219 related articles for article (PubMed ID: 16520104)
1. Adherence, patient preference and dosing frequency: understanding the relationship.
Reginster JY; Rabenda V; Neuprez A
Bone; 2006 Apr; 38(4 Suppl 1):S2-6. PubMed ID: 16520104
[TBL] [Abstract][Full Text] [Related]
2. Once-monthly dosing: an effective step forward.
Reid DM
Bone; 2006 Apr; 38(4 Suppl 1):S18-22. PubMed ID: 16533625
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
4. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
5. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
Rossini M; Viapiana O; Gatti D; Adami S
Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
[TBL] [Abstract][Full Text] [Related]
7. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Gold DT; Safi W; Trinh H
Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
[TBL] [Abstract][Full Text] [Related]
8. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
9. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
10. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.
Reginster JY; Felsenberg D; Cooper C; Stakkestad JA; Miller PD; Kendler DL; Adami S; McClung MR; Bolognese MA; Civitelli R; Dumont E; Bonvoisin B; Recker RR; Delmas PD
Osteoporos Int; 2006 Feb; 17(2):159-66. PubMed ID: 15959614
[TBL] [Abstract][Full Text] [Related]
11. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
[TBL] [Abstract][Full Text] [Related]
12. Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis.
Dempster DW; Bolognese MA
J Clin Densitom; 2006; 9(1):58-65. PubMed ID: 16731432
[TBL] [Abstract][Full Text] [Related]
13. [Further characterization between oral bisphosphonate dosing interval and patient preference--patient preference for daily, weekly and monthly bisphosphonate, based on results of 3,052 outpatients questionnaires].
Ijiri S
Nihon Rinsho; 2013 Dec; 71(12):2223-31. PubMed ID: 24437282
[TBL] [Abstract][Full Text] [Related]
14. [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
García-Hernández P; Carranza-Lira S; Motta-Martínez E
Ginecol Obstet Mex; 2010 Jun; 78(6):322-8. PubMed ID: 20939245
[TBL] [Abstract][Full Text] [Related]
15. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.
Vytrisalova M; Touskova T; Ladova K; Fuksa L; Palicka V; Matoulkova P; Horak P; Stepan J
Climacteric; 2015; 18(4):608-16. PubMed ID: 25495333
[TBL] [Abstract][Full Text] [Related]
16. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
Bonnick SL; Silverman S; Tanner SB; Martens M; Bachmann G; Kohles JD; Civitelli R
J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
Miller PD
Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
[TBL] [Abstract][Full Text] [Related]
18. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
19. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
Emkey R; Koltun W; Beusterien K; Seidman L; Kivitz A; Devas V; Masanauskaite D
Curr Med Res Opin; 2005 Dec; 21(12):1895-903. PubMed ID: 16368038
[TBL] [Abstract][Full Text] [Related]
20. Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study.
Kastelan D; Lozo P; Stamenkovic D; Miskic B; Vlak T; Kolak Z; Milas Ahic J; Altabas V; Crncevic Orlic Z; Korsic M
Clin Rheumatol; 2009 Mar; 28(3):321-6. PubMed ID: 19031095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
